HRP20191322T1 - Antitumorska kombinacija koja sadži kabazitaksel i cisplatin - Google Patents
Antitumorska kombinacija koja sadži kabazitaksel i cisplatin Download PDFInfo
- Publication number
- HRP20191322T1 HRP20191322T1 HRP20191322TT HRP20191322T HRP20191322T1 HR P20191322 T1 HRP20191322 T1 HR P20191322T1 HR P20191322T T HRP20191322T T HR P20191322TT HR P20191322 T HRP20191322 T HR P20191322T HR P20191322 T1 HRP20191322 T1 HR P20191322T1
- Authority
- HR
- Croatia
- Prior art keywords
- cabazitaxel
- combination
- cisplatin
- use according
- administration
- Prior art date
Links
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 title claims 13
- 229960001573 cabazitaxel Drugs 0.000 title claims 13
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title claims 9
- 229960004316 cisplatin Drugs 0.000 title claims 9
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 230000010412 perfusion Effects 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Claims (12)
1. Kombinacija koja sadrži kabazitaksel, koji može biti u obliku bezvodne baze, hidrata ili solvata, i cisplatin, navedena kombinacija je za primjenu kabazitaksela perfuzijom u dozi od 15 do 25 mg/m2 i za primjenu cisplatina perfuzijom u dozi od 75 mg/m2, naznačena time što za uporabu za liječenje raka.
2. Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što je kabazitaksel u obliku solvata.
3. Kombinacija za uporabu prema patentnom zahtjevu 2, naznačena time što je solvat acetatni solvat.
4. Kombinacija za uporabu prema patentnom zahtjevu 3, naznačena time što acetatni solvat sadrži između 5% i 8 masenih % acetona.
5. Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što je za primjenu kabazitaksela perfuzijom u dozi od 15 mg/m2 i za primjenu cisplatina perfuzijom u dozi od 75 mg/m2.
6. Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što se ciklus davanja dvaju antitumorskih sredstava ponavlja s razmakom od tri tjedna između dva davanja kabazitaksela.
7. Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što se kabazitaksel i cisplatin primjenjuju istovremeno, polu-istovremeno, odvojeno, ili raspoređeno tijekom vremenskog perioda.
8. Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što količina kabazitaksela predstavlja od 10 do 90 masenih % kombinacije.
9. Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što se kabazitaksel i cisplatin oba primjenjuju parentalno.
10. Kombinacija za uporabu prema patentnom zahtjevu 9 naznačena time što se kabazitaksel i cisplatin oba primjenjuju intravenski.
11. Farmaceutski komplet, koji sadrži:
(i) prvu galensku formulaciju koja sadrži kabazitaksel u obliku slobodne baze ili adicijske soli s farmaceutski prihvatljivom kiselinom, ili u obliku hidrata ili solvata;
(ii) drugu galensku formulaciju koja sadrži cisplatin; za davanje kabazitaksela perfuzijom u dozi od 15 mg/m2 i za davanje cisplatina perfuzijom u dozi od 75 mg/m2.
obje galenske formulacije (i) i (ii) su namijenjene da se primjenjuju neovisno, svaka primjena s obzirom na drugu je istovremena, odvojena ili raspoređena tijekom vremena naznačen time što je za uporabu za liječenje raka.
12. Farmaceutski komplet za uporabu u skladu sa zahtjevom 11, naznačen time što se ciklus davanja dvaju antitumorskih sredstava ponavlja s razmakom od tri tjedna između dva davanja kabazitaksela.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305204A EP2491925A1 (en) | 2011-02-25 | 2011-02-25 | Antitumoral combination comprising cabazitaxel and cisplatin |
| EP12305109.6A EP2620148A1 (en) | 2012-01-27 | 2012-01-27 | Antitumoral combination comprising cabazitaxel and cisplatin |
| PCT/EP2012/053125 WO2012113897A1 (en) | 2011-02-25 | 2012-02-24 | Antitumoral combination comprising cabazitaxel and cisplatin |
| EP12706546.4A EP2678011B1 (en) | 2011-02-25 | 2012-02-24 | Antitumoral combination comprising cabazitaxel and cisplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191322T1 true HRP20191322T1 (hr) | 2019-10-18 |
Family
ID=45774193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191322TT HRP20191322T1 (hr) | 2011-02-25 | 2019-07-22 | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20140056996A1 (hr) |
| EP (1) | EP2678011B1 (hr) |
| AR (1) | AR085399A1 (hr) |
| CY (1) | CY1122357T1 (hr) |
| DK (1) | DK2678011T3 (hr) |
| ES (1) | ES2745506T3 (hr) |
| HR (1) | HRP20191322T1 (hr) |
| HU (1) | HUE046232T2 (hr) |
| LT (1) | LT2678011T (hr) |
| PL (1) | PL2678011T3 (hr) |
| PT (1) | PT2678011T (hr) |
| SI (1) | SI2678011T1 (hr) |
| TW (1) | TWI598097B (hr) |
| UY (1) | UY33923A (hr) |
| WO (1) | WO2012113897A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103058960B (zh) * | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | 卡巴他赛多晶型形式及其制备方法 |
| TW201540296A (zh) * | 2014-01-13 | 2015-11-01 | Aventis Pharma Sa | 使用卡巴利他賽（ｃａｂａｚｉｔａｘｅl）於患有晚期胃腺癌且於先前化療療程已失敗的病患之用途 |
| CN110384679A (zh) * | 2018-04-16 | 2019-10-29 | 广州铠宝蕊医药科技有限公司 | 卡巴他赛白蛋白纳米粒制剂及其制备方法与应用 |
| WO2022056396A1 (en) * | 2020-09-14 | 2022-03-17 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of cabazitaxel |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5847170A (en) | 1995-03-27 | 1998-12-08 | Rhone-Poulenc Rorer, S.A. | Taxoids, their preparation and pharmaceutical compositions containing them |
| MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
| SI1493556T1 (sl) | 2003-07-02 | 2006-02-28 | Scheuten Glasgroep Bv | Postopek za pripravo protipozarne zasteklitve |
| FR2945211A1 (fr) * | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
-
2012
- 2012-02-24 LT LT12706546T patent/LT2678011T/lt unknown
- 2012-02-24 DK DK12706546.4T patent/DK2678011T3/da active
- 2012-02-24 AR ARP120100612A patent/AR085399A1/es unknown
- 2012-02-24 TW TW101106241A patent/TWI598097B/zh not_active IP Right Cessation
- 2012-02-24 WO PCT/EP2012/053125 patent/WO2012113897A1/en active Application Filing
- 2012-02-24 HU HUE12706546A patent/HUE046232T2/hu unknown
- 2012-02-24 PT PT12706546T patent/PT2678011T/pt unknown
- 2012-02-24 SI SI201231648T patent/SI2678011T1/sl unknown
- 2012-02-24 EP EP12706546.4A patent/EP2678011B1/en not_active Revoked
- 2012-02-24 PL PL12706546T patent/PL2678011T3/pl unknown
- 2012-02-24 UY UY0001033923A patent/UY33923A/es not_active Application Discontinuation
- 2012-02-24 ES ES12706546T patent/ES2745506T3/es active Active
-
2013
- 2013-08-22 US US13/973,432 patent/US20140056996A1/en not_active Abandoned
-
2017
- 2017-07-13 US US15/648,930 patent/US20180153931A1/en not_active Abandoned
-
2019
- 2019-07-22 HR HRP20191322TT patent/HRP20191322T1/hr unknown
- 2019-09-24 CY CY20191101003T patent/CY1122357T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2678011T (lt) | 2019-12-10 |
| US20180153931A1 (en) | 2018-06-07 |
| TWI598097B (zh) | 2017-09-11 |
| TW201249435A (en) | 2012-12-16 |
| ES2745506T3 (es) | 2020-03-02 |
| EP2678011A1 (en) | 2014-01-01 |
| HUE046232T2 (hu) | 2020-02-28 |
| AR085399A1 (es) | 2013-09-25 |
| EP2678011B1 (en) | 2019-06-26 |
| US20140056996A1 (en) | 2014-02-27 |
| WO2012113897A1 (en) | 2012-08-30 |
| SI2678011T1 (sl) | 2019-09-30 |
| UY33923A (es) | 2012-09-28 |
| CY1122357T1 (el) | 2021-01-27 |
| DK2678011T3 (da) | 2019-09-23 |
| PT2678011T (pt) | 2019-09-26 |
| PL2678011T3 (pl) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191322T1 (hr) | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| UA107112C2 (en) | Activator of soluble guanylate cyclase | |
| TN2013000293A1 (en) | Derivatives of azaindazole or diazaindazole type as medicament | |
| SG10201804024VA (en) | Formulations of azaindole compounds | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| JP2013542247A5 (hr) | ||
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| JP2013518107A5 (hr) | ||
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| IN2014MN01919A (hr) | ||
| HRP20160203T1 (hr) | Pripravci koji sadrže 15-hepe i postupci njihove upotrebe | |
| CA2920410C (en) | Thienopiperidine derivative and use thereof | |
| HRP20171693T1 (hr) | Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| JP2014504636A5 (hr) | ||
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| JP2014530181A5 (hr) | ||
| HRP20151340T1 (hr) | Derivati tieno[2,3-d] pirimidina i njihova primjena u lijeäśenju aritmije | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| HRP20171725T1 (hr) | FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I NSAR |